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Background. To date, there is no commercially available vaccine to prevent infectious mononucleosis, a disease
frequently induced by Epstein-Barr virus (EBV) infection in adolescents or adults devoid of preexisting immunity to
the virus.
Methods. A total of 181 EBV-seronegative, healthy, young adult volunteers were randomized in a double-blind
fashion to receive either placebo or a recombinant EBV subunit glycoprotein 350 (gp350)/aluminum hydroxide and
3-O-desacyl-4'-monophosphoryl lipid A (AS04) candidate vaccine in a 3-dose regimen.
Results. The vaccine had demonstrable efficacy (mean efficacy rate, 78.0% [95% confidence interval {CI}, 1.0%–
96.0%]) in preventing the development of infectious mononucleosis induced by EBV infection, but it had no efficacy
in preventing asymptomatic EBV infection. One month after receipt of the final dose of gp350 vaccine, 98.7% of
subjects showed seroconversion to anti-gp350 antibodies (95% CI, 85.5%–97.9%), and they remained anti-gp350
antibody positive for18 months. Furthermore, there were no concerns regarding the safety or reactogenicity of the
gp350/AS04 vaccine.
Conclusion. These data support the clinical feasibility of using an EBV vaccine to prevent infectious mononu-
cleosis.
Trial registration. ClinicalTrials.gov identifier: NCT00430534.
Epstein-Barr virus (EBV) is a common human
-herpesvirus that is prevalent in human populations
worldwide [1]. EBV infection is usually asymptomatic in
children. However, 30%–40% of adolescents (age,15
years) who contract the virus will develop infectious
mononucleosis [2]. The acute phase of illness is charac-
terized by a triad of symptoms—cervical lymphadenop-
athy, fever, and pharyngitis—followed by a general feel-
ing of fatigue and malaise, which may last for several
months. Infectious mononucleosis occasionally may
lead to serious complications, including fulminant he-
patic failure, splenic rupture, and hematologic disor-
ders [3].
After initial infection, the host becomes a lifelong car-
rier of EBV. In rare instances, EBV has been associated
with several oncogenic presentations, including Burkitt
lymphoma, posttransplantation lymphoproliferative
disorders, lymphoma in HIV-infected patients, and na-
sopharyngeal carcinoma [1, 4, 5]. Furthermore, it has
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been suggested that EBV is associated with chronic fatigue syn-
drome [6], Hodgkin disease [7], and multiple sclerosis [8].
At present, there is no commercially available vaccine to pre-
vent EBV-associated disease, although a number of develop-
mental formulations are under investigation. Glycoprotein 350
(gp350) is a viral antigen expressed on the EBV capsid that facil-
itates entry of EBV into B cells by attaching to the CD21 antigen
receptors on their surface. It is targeted by the immune system
after natural infection [9–11] and has therefore attracted con-
siderable interest as a potential vaccine candidate. In the early
1990s, a gp350-based vaccinewas tested in children [12].Despite
the fact that findings regarding anti-gp350 seroconversion and
efficacy were encouraging, this vaccine did not seem to be devel-
oped further, and the findings were not confirmed.
In our early studies of an anti-gp350 EBV vaccine, we showed
a recombinant gp350 subunit/AS04 preparation to be generally
well tolerated and immunogenic [13]. After noting such encour-
aging results, we conducted this phase 2 trial to examine the
immunogenicity and safety of the recombinant viral gp350/
AS04 vaccine and measure its efficacy in preventing infectious
mononucleosis in healthy young adults.
MATERIALS AND METHODS
Vaccine. The gp350/AS04 and placebo vaccines were formu-
lated by GlaxoSmithKline Biologicals (Rixensart, Belgium).
Each dose of vaccine contained 50 g of gp350 and AS04 Adju-
vant System (0.5 mg of aluminum hydroxide and 50 g of 3-O-
desacyl-4'-monophosphoryl lipid A) in a 0.5-mL volume. Each
dose of placebo contained 0.5 mg of aluminum hydroxide in a
0.5-mL volume. Recombinant gp350 was purified from the su-
pernatant of Chinese hamster ovary cells expressing a gp350/220
gene construct with splice-site mutations that prevent popula-
tion of the gp220 isoform (MSTOP gp350) [9]. Cells were cul-
tured in suspension in the absence of fetal bovine serum.
Subjects. The studywas performed at 5 locations across Bel-
gium (Antwerp, Brussels, Charleroi, Leuven, and Liège) between
October 2001 and December 2003. Of the 2145 subjects who
underwent screening, a total of 181 volunteers who were 16–25
years of age and were found to be negative for serological mark-
ers of EBV infection (i.e., had negative antibody titers according
to anti–viral capsid antigen [VCA] immunoglobulin [Ig] G and
IgM ELISA [see the “Serological analysis” subsection below])
were enrolled. All subjects were healthy, as determined by med-
ical examination, and did not meet any of the following exclu-
sion criteria: clinical signs of acute illness or fever; history of
infectious mononucleosis; major congenital defects or serious
chronic illness; history of neurological disorders or seizures; in-
jection drug use; sensitivity to vaccine components; immuno-
suppression, including that due to chronic treatment with
immunosuppressive drugs (such as corticosteroids) or to immu-
nosuppressive or immunodeficient conditions; simultaneous
participation in any other clinical trial; simultaneous receipt of
any other vaccine(s); receipt of immunoglobulins during the
study or during the 3 months before administration of the first
vaccine dose; and pregnancy or lactation. Approval by the local
ethics committee was obtained from the study centers, and each
subject provided written, informed consent. Female volunteers
agreed to use appropriate contraception during the first 7
months of the study, and urine pregnancy testingwas performed
before each vaccine injection.
Study design. Volunteers were randomized in a double-
blind fashion to receive 3 doses of either vaccine or placebo in a
1:1 ratio. Both types of doses were administered intramuscularly
into the deltoid at 0, 1, and 5 months. Blood samples were ob-
tained at the time of medical visits at months 0, 1, 5, 6, and 19 of
the study, for determination of anti-VCA and anti-gp350
antibody levels.
Vaccine efficacy was assessed in all subjects over the 18
months of follow-up after administration of the second injection
(up to month 19 of the study). Subjects were briefed on infec-
tious mononucleosis symptoms and received an information
sheet that recapitulated these symptoms. They were instructed
to record and report any suspicion of infectious mononucleosis
to the investigator, and they were reminded every month to do
so. Each time a case of infectious mononucleosis was suspected,
an additional medical visit was scheduled. Disease symptoms
and date of onset were recorded at the clinic, and blood samples
were collected for laboratory analysis. If infectious mononucle-
osis was confirmed, additional monthly visits were arranged un-
til recovery.
Serological analysis. Assessment of EBV serological status
before vaccination, as well as monitoring of EBV infection dur-
ing the course of the trial, was performed at Henogen (Gosselies,
Belgium). Antibodies to EBV nonvaccine antigens were assessed
using a recombinant anti-VCA IgG and IgM ELISA (Biotest).
Negative ELISA results noted at baseline and positive ELISA re-
sults noted betweenmonths 1 and 18were confirmed using anti-
VCA immunofluorescence against IgG and IgM (Euroimmun).
All results falling within 20% of the ELISA cutoff value, as
defined by themanufacturer, were confirmed using immunoflu-
orescence.
During the trial, anti-gp350 antibody titers were measured by
use of a gp350 ELISA, which was developed and validated at
Henogen. This method was used along with a competition
ELISA, based on the 72A1 monoclonal antibody, to measure
EBV-neutralizing activity [14].
Sample analysis, including hematologic and biochemical
analysis and evaluation of heterophile, cytomegalovirus (CMV),
and toxoplasma antibodies, was performed in a blinded fashion
by study center laboratories.
Case definitions of infectious mononucleosis and EBV
infection. Suspected cases of infectious mononucleosis were
reviewed by an external EBV expert and at data reviewmeetings,
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before the trial was unblinded. Case presentation categories in-
cluded “definite,” “probable,” or “possible” infectiousmononu-
cleosis, as well as asymptomatic EBV infection.
Definite cases of infectious mononucleosis were defined as
cases occurring in subjects who, during the study period, showed
seroconversion to EBV nonvaccine antigens (IgM or IgG anti-
bodies, as assessed by VCA ELISA), accompanied by2 clinical
symptoms related to EBV (e.g., fatigue, sore throat, painful
lymph nodes, fever [body temperature,37°C], excessive sleep-
ing, headache, sore muscles, nausea, sore joints, cough, or rash),
but who did not demonstrate seroconversion to CMV or toxo-
plasma antigens. Suspected cases occurring in subjects who
showed no seroconversion to VCAwere defined as definite non-
cases of infectious mononucleosis.
“Probable” and “possible” clinical presentations were defined
before the study began, to identify subjects who showed sero-
conversion to EBV nonvaccine antigens but for whom incom-
plete data were available or subjects whose clinical presentations
were unclear and for whom an etiology other than EBV was
suspected, respectively. EBV infection, defined by seroconver-
sion to nonvaccine EBV antigens (IgM or IgG antibodies) that
was not accompanied by symptoms of infectious mononucleo-
sis, was recorded as asymptomatic EBV infection.
Data analysis. The trial enrolled 181 healthy adult volun-
teers. Under the assumption of a true vaccine efficacy rate of
90% and an infectiousmononucleosis attack rate of 7%per year,
Fisher’s exact test with a 1-sided significance of   0.05 would
have 80% power to detect a difference in the incidence of infec-
tious mononucleosis, with 83 subjects per group. A distribution
of 10 cases in the placebo group and up to 3 cases in the vaccine
group would reach levels of statistical significance.
The primary end point was the incidence of infectious mono-
nucleosis in vaccine and placebo groups 18months after admin-
istration of the second vaccine dose. The according-to-protocol
(ATP) population was used for primary analyses of vaccine effi-
cacy, which was defined as 1 (attack rate in the vaccine group/
attack rate in the placebo group). A 2-sided 95% confidence
interval (CI) around the vaccine efficacy rate (estimated as 1
relative risk [RR]) was computed (using theMantel-Haenszel CI
for the RR). Odds ratios (ORs) for contracting infectiousmono-
nucleosis were calculated using a 1-sided Fisher’s exact test
(  0.05), with and without stratification for center effects.
Secondary end points included the efficacy of the vaccine in
preventing primary EBV infection (symptomatic and asymp-
tomatic cases) and the immunogenicity of the vaccine in terms
of humoral response, as well as safety and reactogenicity. The
vaccine was differentiated from placebo by use of a 1-sided Fish-
er’s exact test. The main analyses of safety and reactogenicity
were performed using the “intention-to-treat” (ITT) popula-
tion. Attack rates were calculated as the number of cases divided
by the number of subjects, expressed as a percentage.
RESULTS
Demographic characteristics. A total of 181 volunteers, all of
whomwere found to be negative for serological markers of EBV
infection, were randomized to receive placebo or gp350/AS04
vaccine. A total of 90 of 91 participants in the placebo group and
88 of 90 patients in the vaccine group completed the study (until
month 19).
The study groups were well balanced in terms of age, with a
mean age of 20.5 years for subjects in the placebo group and 20.6
years for subjects in the vaccine group. Both groups were simi-
larly well balanced in terms of distributions of sex (percentage of
subjects who were male, 53.8% of the placebo group and 51.1%
of the vaccine group) and race (percentage of subjects who were
white, 96.7% of the placebo group and 97.8% of the vaccine
group).
Efficacy. Two definite cases of infectious mononucleosis
were confirmed in subjects receiving gp350 vaccine, and 8 defi-
nite cases were confirmed in subjects in the placebo group, when
efficacy analysis was ATP based (table 1). This distribution did
not reach statistical significance (P  .06;   0.05, by 1-sided
Fisher’s exact test). In ITT-based efficacy analysis, infectious
mononucleosis caseswere distributed as follows: 9 cases (1 prob-
able and 8 definite) were found in the placebo group and 2 cases













Infectious mononucleosis 8 2 9 2a
Definite 8 2 8 2
Probable 0 0 1 0
Asymptomatic infection 9 11 9 11
Total 17 13 18 13
NOTE. Data are no. of subjects. AS04, aluminum hydroxide and 3-O-desacyl-4'-monophosphoryl lipid A; ATP, according to protocol; gp350, glycoprotein 350;
ITT, intention to treat.
a The difference between the vaccine and placebo group reaches statistical significance (  0.05, by 1-sided Fisher’s exact test).
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(both definite) were found in the vaccine group (P  .03;
  0.05, by 1-sided Fisher’s exact test) (table 1), representing
attack rates of 2.22% per 1.5 years (95% CI, 0.27%–7.80%) for
the vaccine group and 9.89% (95% CI, 4.62%–17.85%) for the
placebo group. Of the 2 cases that occurred in vaccinated sub-
jects, 1 was associated with very limited disease symptoms (low-
grade sore throat and painful lymph nodes) and, consequently,
was on the outer limits of criteria for disease confirmation. In
addition, because this case occurred 3 months after the first vac-
cine injection (figure 1), and because an incubation period of
several weeks can be expected, this individual may have been
infected before he received the second vaccine dose. The second
case occurred in an individual who presented with infectious
mononucleosis 5 months after the first vaccine injection and
who seemed not to be highly responsive to the vaccine on the
basis of the anti-gp350 titer noted at that time (6.5 U vs. a mean
titer of 26.96 U [95%CI, 21.35–34.06 U] for the vaccine group),
which might explain why the individual contracted the disease.
The probable case that occurred in the placebo group could not
be confirmed because clinical symptoms were not adequately
reported to the investigator.
An additional case of infectious mononucleosis was reported
in a placebo recipient 21 months after the second vaccine injec-
tion was administered and before study unblinding took place;
however, it was reported too late to be incorporated into the
database.
Vaccine efficacy, which was measured by the ability of the
vaccine to prevent infectious mononucleosis, was 78.0% (95%
CI, 1%–96%) when the ITT population was used for analysis.
The OR for contracting infectious mononucleosis was 0.11 in
the placebo group and 0.023 in the vaccine group. The estimated
OR for the 2 groups was 4.80 (1-sided 95% CI,1.30), indicat-
ing that the odds of developing a case of infectious mononucle-
osis were 4.8 times more likely in the placebo group than in the
vaccine group. When the data were stratified for center effects,
the estimated common OR was 5.10 (1-sided 95% CI, 1.34).
The difference between the incidence of asymptomatic EBV in-
fections occurring in volunteers receiving vaccine or placebo (11
vs. 9 cases, respectively) did not reach statistical significance.
Immunogenicity. Six months after the first dose of gp350
vaccine was administered (i.e., 1 month after the third dose),
98.7% (95% CI, 85.5%–97.9%) of subjects who had not already
demonstrated conversion for anti-VCA antibodies showed sero-
conversion for anti-gp350 antibodies, as measured by gp350
ELISA (cutoff, 10 U/mL). Geometric mean titers were 356.23 U
(95% CI, 276.22–459.42 U) for the gp350 vaccine group and
2.83 U (95% CI, 2.54–3.14 U) for the placebo group. In com-
parison, the 9 subjects in the placebo group who developed
asymptomatic EBV infection during the course of the trial had
gp350 ELISA titers of 11.9–84.6 U at the fifth medical visit (14
months after the third dose). Competition ELISA values peaked
at 6 months after the first injection, with 69.86% (95% CI,
58.00%–80.06%) of subjects showing seroconversion at that
point in time.
Safety. Study medication was well tolerated, and no subject
discontinued medication for reasons of safety or reactogenicity.
After each of 3 doses, themean percentage of patients presenting
with adverse events was slightly higher in the vaccine group than
in the placebo group: local pain (85.7%, 73.6%, and 73.6% vs.
63.7%, 52.6%, and 58.2%, respectively), redness (20.9%, 26.4%,
and 27.5% vs. 15.4%, 14.3%, and 13.2%, respectively) and swell-
ing (11.0%, 16.5%, and 20.9% vs. 5.5%, 8.8%, and 7.7%, respec-
tively). Systemic adverse events occurred less frequently in the
vaccine group, with no statistical difference noted between
gp350 vaccine and placebo. The most commonly solicited gen-
eral symptoms were fatigue and headache. One case of appendi-
citis was reported in a subject receiving placebo, but this event
was not considered to be related to vaccination.
DISCUSSION
The primary objective of the present phase 2 study was to esti-
mate the efficacy of a recombinant gp350 vaccine in protecting
EBV-seronegative subjects against infectious mononucleosis
during the study period. Although the frequency of infectious
mononucleosis was not statistically different between both
groups in the ATP analysis, the vaccine had demonstrable effi-
cacy (mean efficacy rate, 78.0% [95% CI, 1.0%–96.0%]) when
the incidence of infectiousmononucleosis in the ITT population
was assessed. The number of EBV infections was limited, and the
95%CI of the calculated efficacy was 1.0%–96.0%because of the
small study population. The results of the present study suggest
that 3 doses of vaccine are necessary before full protection is
afforded. Indeed, no case of infectious mononucleosis was de-
Figure 1. Timing of occurrence of infectious mononucleosis in vaccine
and placebo recipients (an intention-to-treat cohort). Arrows denote the
times of vaccination. After completion of the study, 1 additional case of
infectious mononucleosis was reported in the placebo group.
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clared in the vaccine group after completion of the vaccination
schedule, whereas cases still occurred regularly in the placebo
group. Moreover, only after administration of the third vaccine
dose was the level of induced anti-gp350 antibodies found to be
higher than that resulting from natural infection.
The gp350/AS04 vaccine that we used largely prevented the
development of infectious mononucleosis after EBV infection,
but it did not prevent asymptomatic EBV infection. It is note-
worthy that the total number of EBV infections (symptomatic
and asymptomatic cases) was marginally reduced in the vaccine
group compared with the placebo group (13 vs. 18 cases, respec-
tively). It would be of considerable interest to see whether this
trend develops further by evaluating a larger number of subjects.
It would also be interesting, in such a larger panel, to study the
mechanisms of protection that are induced by vaccination—in
particular, the effect on the EBV load after infection, because it
has been suggested that a reduction in this parameter correlates
with protection against infectious mononucleosis [15].
It is unclear whether the gp350 EBV vaccine can prevent other
potential complications of EBV infection, such as posttransplan-
tation lymphoproliferative disorder, whichmay progress to true
B lymphoma (Burkitt or Hodgkin lymphoma) [5, 7, 16]. A vac-
cine that could prevent EBV infection may be of considerable
clinical benefit, especially for patients undergoing organ trans-
plantation or those with immunosuppressive conditions.
This study was not designed to assess the duration of protec-
tion of the gp350/AS04 vaccine. However, as illustrated in figure
1, the time of occurrence of infectiousmononucleosis in vaccine
recipients and placebo recipients in the trials suggests that the
duration of protection after vaccination may exceed 18 months.
This is the first demonstration of the considerable efficacy of a
vaccine to prevent infectiousmononucleosis after EBV infection
in a small study. The gp350 vaccine formulation was well toler-
ated, and there were no specific concerns related to safety. To-
gether, these findings show promise for further exploration of
the use of this gp350/AS04 vaccine in the prevention of infec-
tious mononucleosis.
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